41 patents
Page 2 of 3
Utility
GLUCAGON-GLP-1-GIP Triple Agonist Compounds
25 Nov 21
The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
Filed: 29 Jul 21
Utility
Amylin Analogues
11 Nov 21
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes.
Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
Filed: 21 Jul 21
Utility
Cyclic Peptides Multimers Targeting ALPHA-4-BETA-7 Integrin
21 Oct 21
Mohammed Monzur MORSHED, Sai Kumar CHAKKA, Jennifer L. HICKEY, Manuel Perez VAZQUEZ, Andrew ROUGHTON, Adam Paul KAFAL, Narendrakumar B. PATEL
Filed: 19 Apr 21
Utility
GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) Analogues
7 Oct 21
GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays.
Bjarne Due LARSEN, Yvette Miata PETERSEN
Filed: 21 Jan 21
Utility
Cyclic Peptides Targeting ALPHA-4-BETA-7 Integrin
30 Sep 21
Manuel Perez VAZQUEZ, M. Monzur MORSHED, Jennifer L. HICKEY, Adam Paul KAFAL, James GILLARD, Narendra PATEL, Sai Kumar CHAKKA, Andrew L. ROUGHTON, Marc-André POUPART, Gaoqiang YANG
Filed: 26 Mar 21
Utility
Liquid Formulations of Glucagon Analogues
16 Sep 21
The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and/or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia.
Jesper Skodborg VILLADSEN, Tine Elisabeth Gottschalk BØVING
Filed: 16 Mar 21
Utility
CorrectedAcylated GLP-1/GLP-2 Dual Agonists
12 Aug 21
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
Filed: 6 Apr 20
Utility
Amylin Analogues
22 Apr 21
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes.
Rasmus JUST, Oliver DEMMER, Lise GIEHM, Jesper Skodborg VILLADSEN, Henrik MUNCH, Jesper Mosolff MATHIESEN, Jolanta SKARBALIENE, Maria DERYABINA, Dieter Wolfgang HAMPRECHT
Filed: 6 Aug 20
Utility
Apparatus and Methods for Administering a Pharmaceutical Agent
11 Mar 21
An injection device adapted to be worn on the body of a patient.
Adam STEENSBERG
Filed: 22 Jul 20
Utility
Moving Basal Engine For A Fluid Delivery Device
25 Nov 20
A fluid delivery device comprises a fluid reservoir for containing medicament.
Robert R. Gonnelli
Filed: 27 Jul 20
Utility
Acylated GLP-1/GLP-2 Dual Agonists
23 Sep 20
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
Filed: 5 Apr 20
Utility
Glucagon Analogues
1 Jul 20
The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia.
Ditte RIBER, Lise GIEHM
Filed: 10 Sep 19
Utility
Amylin Analogues
17 Jun 20
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes.
Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
Filed: 24 Oct 19
Utility
Methods and Medical Uses Relating to the Treatment of Hypoglycaemia
3 Jun 20
Methods and medical uses for determining a dose for a glucagon bolus for administration to patients with diabetes for treating mild or moderate hypoglycaemia, while reducing the risk of, or avoiding, rebound hyperglycaemia are described.
Sabrina AANÆS WENDT, Ajenthen RANJAN, Henrik MADSEN, Kirsten NØRGAARD, John BAGTERP JØRGENSEN, Signe SCHMIDT
Filed: 3 Jul 18
Utility
Acylated Glucagon Analogues
20 May 20
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders.
Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
Filed: 11 Sep 19
Utility
Acylated Glucagon Analogue
18 Mar 20
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders.
Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Leo THOMAS
Filed: 12 May 19
Utility
Gap Junction Intercellular Communication Modulators and Their Use for the Treatment of Diabetic Eye Disease
19 Feb 20
The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
Bjarne Due LARSEN, Ulrik MOURITZEN, Dongjoon KIM, Sayon ROY
Filed: 3 May 18
Utility
Dosage Regimes for the Administration of GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) Analogues
1 Jan 20
Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues and their medical use are disclosed, for example in the treatment and/or prevention of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy and radiation therapy.
Kim SONNE, Ulrik MOURITZEN, Peter GLERUP, Palle Bekker JEPPESEN
Filed: 14 Jul 19
Utility
Acylated GLP-1/GLP-2 Dual Agonists
4 Dec 19
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
Filed: 18 Aug 19
Utility
GLP-1/GLP-2 Dual Agonists
6 Nov 19
The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors.
Bjarne Due LARSEN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
Filed: 10 Dec 17